Skip to Main

Joint Bookrunner on Voyager Therapeutics Confidentially Marketed Public Offering

  • Oppenheimer & Co. Inc.
  • January 30, 2024
Oppenheimer & Co. Inc. acted as Joint Bookrunner on Voyager Therapeutics’ $100MM Confidentially Marketed Public Offering

Voyager Therapeutics, Inc. (“Voyager”) (Nasdaq: VYGR), a biotechnology company focused on developing gene therapies and treatments for neurological diseases, announced on Thursday the pricing of its underwritten public offering of 7,777,778 shares of its common stock at a price of $9.00 per share and warrants redeemable for 3,333,333 shares of common stock at a price of $8.999 per share and an exercise price of $0.001. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $100.0 million. Voyager granted the underwriters a 30-day option to purchase up to 1,666,665 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

voyager deal
voyager deal

Voyager recently announced entry into a strategic collaboration and stock purchase agreement with Novartis to advance the Company’s anti-tau antibody program for the treatment of Alzheimer’s disease (AD) and its SOD1 silencing gene therapy program for the treatment of amyotrophic lateral sclerosis (ALS) into clinical development, to advance its tau silencing gene therapy program for the treatment of AD and its anti-amyloid gene therapy program for the treatment of AD in preclinical development, to support its other preclinical development programs, and for working capital and other general corporate purposes. Their pipeline includes wholly-owned and collaborative preclinical programs in AD, ALS, Parkinson’s’ disease, and other diseases of the central nervous system.

Michael Margolis

Michael A. Margolis, R.Ph.


Senior Managing Director, Co-Head of Healthcare, Head of Healthcare Life Sciences

Name: Title:


This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.

2023 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 6300385.1